CA2652205A1 - Low molecular weight heparin composition and uses thereof - Google Patents

Low molecular weight heparin composition and uses thereof Download PDF

Info

Publication number
CA2652205A1
CA2652205A1 CA002652205A CA2652205A CA2652205A1 CA 2652205 A1 CA2652205 A1 CA 2652205A1 CA 002652205 A CA002652205 A CA 002652205A CA 2652205 A CA2652205 A CA 2652205A CA 2652205 A1 CA2652205 A1 CA 2652205A1
Authority
CA
Canada
Prior art keywords
lmwh
composition
activity
reh
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002652205A
Other languages
English (en)
French (fr)
Inventor
Mallik Sundaram
Ganesh Venkataraman
Patricia Oliver
Yiming Yao
Zainab Sirajbhai Mamuwala
Ian Fier
Yi Wei Qi
Zachary Shriver
Ishan Capila
Nur Sibel Gunay
Daniela Beccati
Cuihua Liu
Corinne Bauer
Ying Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2652205A1 publication Critical patent/CA2652205A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002652205A 2006-05-25 2007-05-24 Low molecular weight heparin composition and uses thereof Abandoned CA2652205A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US80913606P 2006-05-25 2006-05-25
US60/809,136 2006-05-25
US84957806P 2006-10-04 2006-10-04
US60/849,578 2006-10-04
US84962806P 2006-10-05 2006-10-05
US60/849,628 2006-10-05
PCT/US2007/069626 WO2007140231A2 (en) 2006-05-25 2007-05-24 Low molecular weight heparin composition and uses thereof

Publications (1)

Publication Number Publication Date
CA2652205A1 true CA2652205A1 (en) 2007-12-06

Family

ID=38722686

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002652205A Abandoned CA2652205A1 (en) 2006-05-25 2007-05-24 Low molecular weight heparin composition and uses thereof

Country Status (7)

Country Link
US (2) US8609632B2 (enExample)
EP (3) EP2019843A2 (enExample)
JP (1) JP2009538386A (enExample)
CN (1) CN101495517B (enExample)
AU (1) AU2007267561B2 (enExample)
CA (1) CA2652205A1 (enExample)
WO (1) WO2007140231A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2402753A1 (en) 2002-03-11 2012-01-04 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
EP2019843A2 (en) 2006-05-25 2009-02-04 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US7790466B1 (en) * 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009105522A1 (en) * 2008-02-20 2009-08-27 Momenta Pharmaceuticals, Inc. Methods of making low molecular weight heparin compositions
US20100036310A1 (en) * 2008-08-05 2010-02-11 Hillman Robert S Integrated patient management and control system for medication delivery
CN101711771B (zh) * 2008-10-07 2015-12-09 上海喜恩医药科技发展有限公司 一种肝素衍生的多糖混合物及其制法和药物组合物
EP2256137A1 (en) * 2009-05-05 2010-12-01 Sanofi-Aventis Novel sulfated octasaccharide and its use as antithrombotic agent
EP2256139A1 (en) * 2009-05-05 2010-12-01 Sanofi-Aventis Novel sulfated heptasaccharide and its use as antithrombotic agent
EP2256138A1 (en) * 2009-05-05 2010-12-01 Sanofi-Aventis Novel acylated 1,6-anhhydro decasaccharide and its use as antithrombotic agent
EP2256136A1 (en) * 2009-05-05 2010-12-01 Sanofi-Aventis Novel acylated decasaccharides and their use as antithrombotic agents
US8834807B2 (en) * 2009-08-12 2014-09-16 Caliper Life Sciences, Inc. Device and method for improving sample injection and stacking
FR2949114B1 (fr) * 2009-08-14 2011-08-26 Sanofi Aventis OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2011031299A1 (en) * 2009-08-28 2011-03-17 Mount Sinai School Of Medicine Of New York University Intrapericardial injections
EP2480237A1 (en) * 2009-09-23 2012-08-01 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
MX2012006265A (es) 2009-12-03 2012-07-25 Opko Health Inc Formulaciones disacaridas hipersulfatadas.
CN102791742B (zh) * 2010-01-19 2014-12-24 动量制药公司 评价肝素制剂
JP5982361B2 (ja) * 2010-04-16 2016-08-31 モメンタ ファーマシューティカルズ インコーポレイテッド 組織標的化方法
CA2795868A1 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
EP2655421B1 (en) 2010-12-23 2022-02-09 The University of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
WO2012100733A1 (zh) * 2011-01-28 2012-08-02 杭州九源基因工程有限公司 一种基于毛细管电泳的依诺肝素钠精细结构测定方法
WO2012115952A1 (en) * 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
DK2794665T3 (da) * 2011-12-19 2018-01-29 Dilafor Ab Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
CN103059165B (zh) * 2012-12-26 2015-04-29 安徽丰原药业股份有限公司 一种多糖酰化物及其制备方法
CN103204958B (zh) * 2013-04-24 2015-04-01 深圳赛保尔生物药业有限公司 一种低乙醇残留的那曲肝素钙生产工艺
US10016449B2 (en) 2013-05-28 2018-07-10 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
US9951149B2 (en) 2013-06-17 2018-04-24 The University Of North Carolina At Chapel Hill Reversible heparin molecules and methods of making and using the same
CN103788232A (zh) * 2013-12-23 2014-05-14 深圳市海普瑞药业股份有限公司 一种硫酸乙酰肝素十糖及其制备方法和应用
CN104193849B (zh) * 2014-08-13 2016-08-17 南京健友生化制药股份有限公司 一种依诺肝素钠的生产方法
US10688249B2 (en) * 2015-06-11 2020-06-23 Virchow Biotech Pvt. Ltd. Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
US20190002596A1 (en) * 2015-12-30 2019-01-03 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Sulfated heparin oligosaccharide and preparation method and application thereof
EP3401686B1 (en) * 2016-01-07 2022-10-05 Fujimori Kogyo Co., Ltd. Method for analyzing blood characteristics
CN105461831A (zh) * 2016-01-08 2016-04-06 东营天东制药有限公司 一种快速分离快速移动肝素与硫酸皮肤素的方法
RU2641058C1 (ru) * 2016-11-17 2018-01-15 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ профилактики венозной тромбоэмболии у больных раком шейки матки
CN108117614B (zh) * 2016-11-29 2020-09-04 北京碧澄生物科技有限公司 低分子量肝素
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
US11903963B2 (en) 2017-03-10 2024-02-20 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
EP3691653B1 (en) 2017-11-03 2025-03-12 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
WO2019246264A1 (en) 2018-06-20 2019-12-26 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
WO2022015794A1 (en) 2020-07-14 2022-01-20 Optimvia, Llc Methods for synthesizing non-anticoagulant heparan sulfate
JP2022540849A (ja) 2019-07-09 2022-09-20 オプティムヴィア、エルエルシー 抗凝固性多糖類の合成方法
WO2021253008A1 (en) * 2020-06-12 2021-12-16 Ihp Therapeutics Inc. Partially desulfated heparin for treating coronaviral infections
EP4326782A1 (en) * 2021-05-12 2024-02-28 Nexeos Diagnostics, Inc. Methods of manufacturing a high molecular weight heparin compound
KR20250063537A (ko) * 2023-11-01 2025-05-08 건국대학교 글로컬산학협력단 저분자량 헤파린 및 지질이 결합되어 자가 조립된 나노 입자, 이의 제조방법 및 이의 용도

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK196986D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
FR2663639B1 (fr) 1990-06-26 1994-03-18 Rhone Poulenc Sante Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.
US5707973A (en) 1991-04-23 1998-01-13 Rhone-Poulenc Rorer S.A. Sulfated polysaccharids for treatment or prevention of thromboses
US5849721A (en) * 1992-02-07 1998-12-15 Rhone-Poulenc Rorer S.A. Sulfated polysaccharides obtained from heparin, preparation process, pharmaceutical composition and use thereof
FR2687158B1 (fr) 1992-02-07 1995-06-30 Rhone Poulenc Rorer Sa Polysaccharides sulfates, procede de preparation, composition pharmaceutique et utilisation.
US5681733A (en) 1994-06-10 1997-10-28 Ibex Technologies Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum
FR2723847A1 (fr) * 1994-08-29 1996-03-01 Debiopharm Sa Compositions antithrombotiques et non hemorragiques a base d'heparine, procede pour leur preparation et applications therapeutiques.
US5744457A (en) 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
CA2293595A1 (en) 1997-06-06 1998-12-10 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
US20010046974A1 (en) 1997-06-06 2001-11-29 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
US5896789A (en) 1997-10-09 1999-04-27 Chicago Pneumatic Tool Company Ratchet wrench head
JP4226101B2 (ja) 1998-05-12 2009-02-18 株式会社アルバック 静電チャックプレート表面からの基板離脱方法
US20020009782A1 (en) 1999-06-03 2002-01-24 Daphna Miron Heparin and heparan sulfate derived oligosaccharides and a method for their manufacture
PL353335A1 (en) * 1999-06-30 2003-11-17 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors
ES2231303T3 (es) 2000-01-10 2005-05-16 Dieter Welzel Heparina con masa molecular media.
AU4351201A (en) 2000-03-08 2001-09-17 Massachusetts Inst Technology Heparinase iii and uses thereof
US6608042B2 (en) * 2000-03-28 2003-08-19 Aventis Pharma, S.A. Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
US6969705B2 (en) 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
FR2811992B1 (fr) * 2000-07-21 2003-07-04 Aventis Pharma Sa Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
ES2324701T3 (es) 2000-09-12 2009-08-13 Massachusetts Institute Of Technology Metodos y productos relacionados con heparina de peso molecular bajo.
AU2440802A (en) 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
US20030050802A1 (en) 2001-04-03 2003-03-13 Richard Jay Medical service and prescription management system
WO2003018032A1 (en) 2001-08-28 2003-03-06 Leo Pharma A/S Antithrombotic compositions comprising low molecular weight heparin and low molecular weight dermatan sulphate
US7084118B2 (en) 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
EP2402753A1 (en) 2002-03-11 2012-01-04 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
FR2845686B1 (fr) * 2002-10-10 2013-08-30 Aventis Pharma Sa Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
FR2857971B1 (fr) * 2003-07-24 2005-08-26 Aventis Pharma Sa Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CN1268650C (zh) * 2003-12-24 2006-08-09 兆科药业（合肥）有限公司 一种低亚硝酸盐含量的低分子肝素钙的制备方法
RU2295538C2 (ru) 2005-03-01 2007-03-20 Гематологический научный центр РАМН Способ получения гепаринов с низкой молекулярной массой
AU2007244927B2 (en) 2006-04-24 2012-01-12 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
EP2019843A2 (en) 2006-05-25 2009-02-04 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof

Also Published As

Publication number Publication date
CN101495517A (zh) 2009-07-29
AU2007267561B2 (en) 2012-05-17
JP2009538386A (ja) 2009-11-05
EP2019843A2 (en) 2009-02-04
AU2007267561A1 (en) 2007-12-06
EP2404939A2 (en) 2012-01-11
EP2447285A3 (en) 2013-01-16
US20070287683A1 (en) 2007-12-13
WO2007140231A3 (en) 2008-12-04
US20100305022A1 (en) 2010-12-02
WO2007140231A2 (en) 2007-12-06
CN101495517B (zh) 2012-10-10
US8609632B2 (en) 2013-12-17
EP2404939A3 (en) 2012-03-21
EP2447285A2 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
AU2007267561B2 (en) Low molecular weight heparin composition and uses thereof
JP4828795B2 (ja) 硫酸化多糖類の分析
EP2205642B1 (en) Non-anticoagulant polysaccharide compositions
Millet et al. Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutaneous route
Casu et al. Structural and conformational aspects of the anticoagulant and antithrombotic activity of heparin and dermatan sulfate
JP5351770B2 (ja) ビオチンまたはビオチン誘導体との少なくとも１つの共有結合を含む低分子量ヘパリン、これらの作製方法およびそれらの使用。
IE66341B1 (en) Mixtures of low molecular weight polysaccharides and their preparation and use
US20110076729A1 (en) Methods of making low molecular weight heparin compositions
Fareed et al. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile
US5721357A (en) Preparation of sulfated polysaccharides for treatment or prevention of thromboses
US20120322760A1 (en) Methods of treatment with a low molecular weight heparin composition
Mousa The low molecular weight heparin, tinzaparin, in thrombosis and beyond
AU671817B2 (en) Sulphated polysaccharides, preparation thereof, pharmaceutical composition and use thereof
RU2451515C2 (ru) Композиции гепарина низкой молекулярной массы и их применение
Fareed et al. Low molecular weight heparins: a developmental perspective
HK1134934A (en) Low molecular weight heparin composition and uses thereof
Green The heparins: Basic and clinical aspects
Hernaningsih et al. Examination of Laboratory for Monitoring Heparin Anticoagulant
Jeske et al. Pharmacologic profile of a low-molecular-weight heparin depolymerized by γ-irradiation
Lee Dalteparin sodium in the management of thromboembolic disorders
Saivin et al. Antithrombotic activity, bleeding effect and pharmacodynamics of a succinyl derivative of dermatan sulphate in rabbits
HK1146074B (en) Non-anticoagulant polysaccharide compositions
HK1140220A (en) Low molecular weight heparins including at least one covalent bond with biotin or a biotin derivative, method for making same and use thereof
HK1199893A1 (en) Use of chemically modified heparin derivates in sickle cell disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141118